Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients

Stopped Termination following reassessment of the potential benefit-risk of AVE0657

Conditions

• Heart Failure
• Sleep Apnea Syndromes
• Cheyne-Stokes Respiration

Interventions

• DRUG: AVE0657
• DRUG: placebo

Sponsor

Sanofi